Home

Correction: Cephalon Story

By Associated Press
June 23, 2008 | Comments (0)

Recs

0

In a June 20 story about Cephalon Inc., The Associated Press reported erroneously that Leerink Swann analyst Gary Nachman expects Treanda to gain favor as a lung cancer treatment. He expects the drug to gain market share as a leukemia treatment.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

DocumentId: 670107, ~/articles/articlehandler.aspx, 12/2/2008 4:17:40 AM,

Sign up for FREE Motley Fool site access!

Already registered? Login Here

It’s FREE! Enter your email address, and we’ll rush you to the article you're looking for right now.

Privacy / Legal Information

We will use your email address only to keep you informed about updates to our web site and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.